Maxigen Biotech (TPE:1783) Cyclically Adjusted PS Ratio: (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.90
GF Value NT$61.49
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Maxigen Biotech  (TPE:1783) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Maxigen Biotech Cyclically Adjusted PS Ratio Related Terms


Maxigen Biotech Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Cyclically Adjusted PS Ratio Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.77 8.05 7.93 7.41 5.90

Maxigen Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.33 6.14 6.41 5.90 0.00

TPE:1783 vs ISRG, BDX, MDLN: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maxigen Biotech Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Maxigen Biotech's Cyclically Adjusted PS Ratio falls into.


TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Maxigen Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, Maxigen Biotech's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.115/330.2130*330.2130
=2.115

Current CPI (Mar. 2026) = 330.2130.

Maxigen Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 1.087 241.018 1.489
201609 1.146 241.428 1.567
201612 1.301 241.432 1.779
201703 1.155 243.801 1.564
201706 1.433 244.955 1.932
201709 1.306 246.819 1.747
201712 1.386 246.524 1.857
201803 1.190 249.554 1.575
201806 1.301 251.989 1.705
201809 1.330 252.439 1.740
201812 1.047 251.233 1.376
201903 1.030 254.202 1.338
201906 1.465 256.143 1.889
201909 1.393 256.759 1.792
201912 1.354 256.974 1.740
202003 1.281 258.115 1.639
202006 1.472 257.797 1.885
202009 1.470 260.280 1.865
202012 1.517 260.474 1.923
202103 1.379 264.877 1.719
202106 1.519 271.696 1.846
202109 1.632 274.310 1.965
202112 2.181 278.802 2.583
202203 1.381 287.504 1.586
202206 1.711 296.311 1.907
202209 1.816 296.808 2.020
202212 1.836 296.797 2.043
202303 1.680 301.836 1.838
202306 1.919 305.109 2.077
202309 1.773 307.789 1.902
202312 1.658 306.746 1.785
202403 1.435 312.332 1.517
202406 1.923 314.175 2.021
202409 1.967 315.301 2.060
202412 2.286 315.605 2.392
202503 1.965 319.799 2.029
202506 2.338 322.561 2.393
202509 2.234 324.800 2.271
202512 2.476 324.054 2.523
202603 2.115 330.213 2.115

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.90 is trading 33.5% below its estimated GF Value™ of NT$61.49. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: NT$61.49 vs. price of NT$40.90 (33.5% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.90
Price
NT$61.49
GF Value